• Dual-Action Inhibitors Reshape p38α Dephosphorylation

  2026-09-07

  The reference preprint shows that selected kinase inhibitors can do more than occupy the p38α catalytic site: they can also expose its activation-loop phosphothreonine to the phosphatase WIP1. Structural and biochemical results support a conformation-directed strategy for combining kinase inhibition with accelerated dephosphorylation, while also highlighting the need to test cellular translation separately.

• T0070907: PPARγ Antagonist Workflow

  2026-09-07

  T0070907 is a covalent, high-affinity PPARγ antagonist for separating receptor-driven transcription from downstream phenotypes. This workflow applies it to reporter assays, adipogenesis inhibition, RXRα/PPARγ studies, foam-cell inflammation, and cell cycle G2/M arrest while emphasizing controls that distinguish on-target effects from cytotoxicity.

• Imatinib (STI571) Workflow for Kinase Studies

  2026-09-05

  Imatinib (STI571) turns PDGFR, c-Kit, and Abl phosphorylation into experimentally tractable endpoints for cancer biology research. This workflow pairs defined kinase inhibition with proliferation assays and high-resolution imaging concepts from porous graphene mass spectrometry imaging.

• Berberine, PPARγ, and SASP in Atherosclerosis

  2026-09-04

  The reference study identifies an RXRα/PPARγ/NEDD4 mechanism through which berberine suppresses SASP-associated inflammation in macrophage-derived foam cells and ApoE−/− atherosclerosis models. Its combination of transcriptomics, cellular assays, plaque analysis, and macrophage-specific RXRα knockdown provides a mechanistic framework for studying inflammatory aging in vascular disease.

• CAPE in NF-κB Neurodegeneration Assays

  2026-09-04

  Caffeic Acid Phenethyl Ester (CAPE) is a DMSO-soluble research tool for dissecting NF-κB-driven inflammation, tumor invasion, angiogenesis, and neuronal injury. This guide translates its reported activity into practical dose-finding, zebrafish imaging, cytokine, VEGF, and matrix metalloproteinase workflows with built-in controls and troubleshooting.

• Z-LEHD-FMK and the Logic of Caspase-9 Proof

  2026-09-03

  A translational framework for using Z-LEHD-FMK to distinguish caspase-9-dependent apoptosis from downstream executioner activity, with practical guidance drawn from recent melanoma research and broader cancer and neuroprotection models.

• EdU Imaging Kits (Cy5) for S-Phase Analysis

  2026-09-03

  EdU Imaging Kits (Cy5) provide a click-chemistry method for measuring DNA synthesis during S phase by fluorescence microscopy or flow cytometry. This 5-ethynyl-2'-deoxyuridine imaging kit preserves cellular morphology and avoids the DNA denaturation required by many BrdU workflows.

• Linoleic Acid C3108: Reliable Cell Assays

  2026-09-02

  This scenario-driven guide explains how Linoleic Acid (SKU C3108) can improve experimental control in viability, oxidative-stress, erythrocyte, migration, and nutritional-deficiency workflows. It connects practical solvent and storage decisions with current evidence on lipid-mediated signaling while distinguishing documented product properties from protocol recommendations.

• Exemestane: Steroidal Aromatase Inhibitor Guide

  2026-09-02

  Exemestane is a selective, irreversible steroidal aromatase inhibitor that suppresses estrogen biosynthesis by inactivating aromatase. Its reported biochemical potency, solvent compatibility, and storage requirements make it a useful tool for breast cancer research and hormone-dependent assay development.

• iPSC-Based Trial Selection for Ultrarare Disease

  2026-09-01

  Sequiera et al. developed a patient-specific iPSC platform to prescreen therapies for an ultrarare Leigh-like syndrome caused by poorly characterized ECHS1 variants. The platform linked cellular drug responses with subsequent clinical decision-making, illustrating how disease modeling can reduce uncertainty before enrolling patients with novel mutations in clinical trials.

• Sulfisomidine Workflows for Enzyme and Microbial Studies

  2026-09-01

  Sulfisomidine, also known as sulfamethin, connects PABA-dependent bacterial metabolism with hPON1 enzyme studies, making it a versatile reagent for mechanistic assays. This guide translates historical pharmacokinetic observations into practical workflows for reproducible inhibition, antimicrobial, cell-based, and degradation experiments.

• STING Agonist-1: From Signaling to TLS

  2026-08-31

  A translational perspective on how STING agonist-1 can help dissect the STING–TRAF2–IRF4 axis, B-cell activation, and tertiary lymphoid structure biology in cancer and inflammation research.

• CD59–JAK2–STAT3 Signaling in Pancreatic Cancer

  2026-08-31

  A 2026 study identifies CD59 as a tumor cell-intrinsic driver of pancreatic cancer rather than only a complement-protective membrane protein. The work connects CD59 to a JAK2–STAT3–CACNA1D signaling axis and shows why simultaneous targeting of CD59 or STAT3 with KRAS may help counter adaptive resistance.

• 5-Methyl-CTP Workflow for Durable mRNA

  2026-08-30

  Learn how 5-Methyl-CTP can be integrated into in vitro transcription to support more persistent, translatable mRNA for expression assays and vaccine-oriented research. The workflow also shows how to evaluate modified transcripts in engineered outer membrane vesicle delivery systems without confusing payload chemistry with carrier performance.

• Modeling Breast Cancer Relapse with PyMT ProTracer

  2026-08-29

  The reference study introduces a dual-recombinase proliferation-tracing and ablation system in spontaneous PyMT mammary tumors. By selectively removing recently proliferating cells and profiling the residual disease with single-cell RNA sequencing, the model reveals cellular and microenvironmental features associated with relapse.

8019 records 1/535 page Next 12345 下5页 Last page